Journal article

Heterologous vaccine effects

Mitra Saadatian-Elahi, Peter Aaby, Frank Shann, Mihai G Netea, Ofer Levy, Jacques Louis, Valentina Picot, Michael Greenberg, William Warren

Vaccine | ELSEVIER SCI LTD | Published : 2016

Abstract

The heterologous or non-specific effects (NSEs) of vaccines, at times defined as "off-target effects" suggest that they can affect the immune response to organisms other than their pathogen-specific intended purpose. These NSEs have been the subject of clinical, immunological and epidemiological studies and are increasingly recognized as an important biological process by a growing group of immunologists and epidemiologists. Much remain to be learned about the extent and underlying mechanisms for these effects. The conference "Off-target effects of vaccination" held in Annecy-France (June 8-10 2015) intended to take a holistic approach drawing from the fields of immunology, systems biology, ..

View full abstract

Grants

Awarded by ERC Consolidator Grant


Awarded by Global Health award from the Bill & Melinda Gates Foundation


Awarded by Grand Challenges Explorations award from the Bill & Melinda Gates Foundation


Awarded by NIH


Awarded by National Institute of Allergy & Infectious Diseases Adjuvant Discovery Program


Awarded by Danish Council for Development Research, Ministry of Foreign Affairs, Denmark


Awarded by European Union FP7 support for OPTIMUNISE


Awarded by Danish National Research Foundation


Funding Acknowledgements

MGN was supported by an ERC Consolidator Grant (#310372).OL's laboratory is supported by Global Health (OPPGH5284) and Grand Challenges Explorations (OPP1035192) awards from the Bill & Melinda Gates Foundation, by NIH grants 1R01AI100135-01 and 3R01AI067353-05S1 as well as National Institute of Allergy & Infectious Diseases Adjuvant Discovery Program Contract No. HHSN272201400052C and by a philanthropic gift from Henry and Carol Goldberg to the Precision Vaccines Program.PA's work on non-specific effects of vaccines has been supported by the Danish Council for Development Research, Ministry of Foreign Affairs, Denmark [grant number 104.Dan.8.f.], Novo Nordisk Foundation, European Union FP7 support for OPTIMUNISE (grant: Health-F3-2011-261375) and by a grant from the Danish National Research Foundation (DNRF108).